Drug Profile
Doravirine/lamivudine/tenofovir disoproxil fumarate - Merck & Co
Alternative Names: DELSTRIGO; DOR/3TC/TDF; MK-1439/lamivudine/tenofovir disoproxil fumarate; MK-1439ALatest Information Update: 19 Oct 2023
Price :
$50
*
At a glance
- Originator Merck Sharp & Dohme
- Developer Merck Sharp & Dohme; National Institute of Allergy and Infectious Diseases
- Class Antiretrovirals; Deoxyribonucleosides; Dideoxynucleosides; Nitriles; Phosphonic acids; Purines; Pyridones; Pyrimidine nucleosides; Small molecules; Triazoles
- Mechanism of Action Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed HIV-1 infections
Most Recent Events
- 07 Sep 2023 Merck Sharp & Dohm completes the phase III DRIVE-AHEAD phase III trial in HIV-1 infections (Treatment-naive) in USA, Australia, Belgium, Canada, Chile, Colombia, Denmark, Germany, Guatemala, Hondura, Israel, Mexico, New Zealand, Peru, Portugal, Puerto Rico, Russia, South Africa, Spain, Switzerland, Taiwan, Thailand, the Netherlands and United Kingdom (PO) (NCT02403674) (EudraCT2014-003382-17)
- 05 Sep 2023 Merck Sharp & Dohm completes the phase III DRIVE-SHIFT trial in HIV-1 infections (Treatment-experienced) in USA, Argentina, Austria, Belgium, Canada, Denmark, Germany, Guatemala, Peru, Poland, Puerto Rico, Spain, Switzerland, Italy and the United Kingdom (PO) (NCT02397096) (EudraCT2014-005550-18)
- 02 Aug 2022 Registered for HIV-1 infections (Treatment-naive, In children, In adolescents) in Norway, Iceland, European Union, Liechtenstein (PO) before August 2022 (Merck pipeline, August 2022)